These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27518403)

  • 1. Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial.
    Lin H; Huang L; Zhou J; Lin K; Wang H; Xue X; Xia C
    Arch Virol; 2016 Nov; 161(11):3073-80. PubMed ID: 27518403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of Jinzhen oral liquid for hand foot and mouth disease: a randomized, multi-center, double-blind, placebo-controlled trial.
    Liu J; Zhang GL; Huang GQ; Li L; Li CP; Wang M; Liang XY; Xie D; Yang CM; Li Y; Sun XR; Zhang HS; Wan BS; Zhang WH; Yu H; Zhang RY; Yu YN; Wang Z; Wang YY
    PLoS One; 2014; 9(4):e94466. PubMed ID: 24722423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection.
    Huang X; Zhang X; Wang F; Wei H; Ma H; Sui M; Lu J; Wang H; Dumler JS; Sheng G; Xu B
    PLoS One; 2016; 11(2):e0148907. PubMed ID: 26882102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease].
    Zhang HP; Wang L; Qian JH; Cai K; Chen YH; Zhang QL; Yu HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Mar; 16(3):272-6. PubMed ID: 24661520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of ribavirin aerosol on viral exclusion of patients with hand-foot-mouth disease].
    Pan S; Qian J; Gong X; Zhou Y
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1563-6. PubMed ID: 25146745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduning injection for fever, rash, and ulcers in children with mild hand, foot, and mouth disease: a randomized controlled clinical study.
    Zhang G; Zhao J; He L; Yan S; Zhuo Z; Zheng H; Mu Y; Li S; Zhang X; Huang J; Li X; Liu J; Wan H; Wei C; Xiao W
    J Tradit Chin Med; 2013 Dec; 33(6):733-42. PubMed ID: 24660604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of
    Lin H; Zhou J; Lin K; Wang H; Liang Z; Ren X; Huang L; Xia C
    Biomed Res Int; 2016; 2016():5697571. PubMed ID: 27840828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    El-Karaksy HM; Mogahed EA; El-Raziky MS; Saleh D; Besheer M; Mubarak S
    J Interferon Cytokine Res; 2016 Jan; 36(1):1-8. PubMed ID: 26406390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.
    Lawitz E; Godofsky E; Rouzier R; Marbury T; Nguyen T; Ke J; Huang M; Praestgaard J; Serra D; Evans TG
    Antiviral Res; 2011 Mar; 89(3):238-45. PubMed ID: 21255610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema.
    Hubiche T; Schuffenecker I; Boralevi F; Léauté-Labrèze C; Bornebusch L; Chiaverini C; Phan A; Maruani A; Miquel J; Lafon ME; Lina B; Del Giudice P;
    Pediatr Infect Dis J; 2014 Apr; 33(4):e92-8. PubMed ID: 24463804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
    Roomer R; Bergmann JF; Boonstra A; Hansen BE; Haagmans BL; Kwadijk-de Gijsel S; van Vuuren AJ; de Knegt RJ; Janssen HL
    Antivir Ther; 2012; 17(3):509-17. PubMed ID: 22300892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the efficacy and safety of magnesium sulfate for management of autonomic nervous system dysregulation in Vietnamese children with severe hand foot and mouth disease.
    Phan QT; Phung LK; Truong KH; Huynh TT; Phạm GT; Nguyen BN; Tran QT; Huynh VNT; Nguyen TTM; Le TPK; Le NNT; Sabanathan S; van Doorn HR; Van Le T; Nguyen TD; Merson L; Nguyen DTP; Geskus R; Nguyen HT; Nguyen CVV; Wills B
    BMC Infect Dis; 2019 Aug; 19(1):737. PubMed ID: 31438878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparative study of Chinese herbal medicine Jinlianqingre Effervescent Tablets in combination with conventional therapy for the treatment of uncomplicated hand, foot, and mouth disease.
    He LY; Zhang GL; Yan SY; Liu Y; Zhao CS; Wang XL; Li Y; Mi YQ; Liu YM; Li CP; Kou YH; Li Y; Chang K; Meng XL; Sun XJ; Zhao T; Li J; Wang YY; Liu BY
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1429-37. PubMed ID: 24643639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children.
    Li JX; Song YF; Wang L; Zhang XF; Hu YS; Hu YM; Xia JL; Li J; Zhu FC
    Expert Rev Vaccines; 2016; 15(1):129-37. PubMed ID: 26460695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
    Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and interferon-modulating efficacy of a combination of rectal and topical dosage forms of interferon-α2b in acute respiratory infections.
    Kalyuzhin OV; Ponezheva ZB; Kupchenko AN; Shuvalov AN; Guseva TS; Parshina OV; Malinovskaya VV; Akimkin VG
    Ter Arkh; 2018 Nov; 90(11):48-54. PubMed ID: 30701815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.